Europe Companion Diagnostics Market Forecast 2022-2030
Description
Europe Companion Diagnostics Market Forecast 2022-2030
KEY FINDINGS
The Europe companion diagnostics market is anticipated to register a CAGR of 13.06% over the forecasted years of 2022 to 2030. The top drivers propelling the regional market’s growth include the increasing focus on collaborative research and development towards advancing precision medicine technologies and the surging need for technologically advanced medical diagnostics.
MARKET INSIGHTS
The Europe companion diagnostics market growth evaluation encompasses an in-depth assessment of the United Kingdom, the Netherlands, Italy, France, Germany, Spain, Poland, and Rest of Europe. Nearly 99% of the population in France is covered by statutory health insurance (Assurance-Maladie), overseen by the Hauté Autorite de Santé (HAS). Although the country’s national healthcare system is considered among the most considerate, France is aiming to minimize healthcare expenditure to control government spending, as well. Nevertheless, the market penetration rate of companion diagnostics is higher in the country on account of its broad reimbursement coverage.
In comparison, the majority of companion diagnostic testing in Spain is executed in the outpatient hospital site. Besides, the country’s hospital funding system primarily relies upon the global budget since neither national price reference coding nor reimbursement coding is available for companion diagnostics. While established hospitals in Spain commission companion diagnostics tests by virtue of public tendering, smaller hospitals organize tenders at a regional level. Therefore, these factors are anticipated to augment the companion diagnostics market growth in Europe over the estimated period.
COMPETITIVE INSIGHTS
Some of the leading firms operating in the market include Almac Group, Biocartis, Biomerieux, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
KEY FINDINGS
The Europe companion diagnostics market is anticipated to register a CAGR of 13.06% over the forecasted years of 2022 to 2030. The top drivers propelling the regional market’s growth include the increasing focus on collaborative research and development towards advancing precision medicine technologies and the surging need for technologically advanced medical diagnostics.
MARKET INSIGHTS
The Europe companion diagnostics market growth evaluation encompasses an in-depth assessment of the United Kingdom, the Netherlands, Italy, France, Germany, Spain, Poland, and Rest of Europe. Nearly 99% of the population in France is covered by statutory health insurance (Assurance-Maladie), overseen by the Hauté Autorite de Santé (HAS). Although the country’s national healthcare system is considered among the most considerate, France is aiming to minimize healthcare expenditure to control government spending, as well. Nevertheless, the market penetration rate of companion diagnostics is higher in the country on account of its broad reimbursement coverage.
In comparison, the majority of companion diagnostic testing in Spain is executed in the outpatient hospital site. Besides, the country’s hospital funding system primarily relies upon the global budget since neither national price reference coding nor reimbursement coding is available for companion diagnostics. While established hospitals in Spain commission companion diagnostics tests by virtue of public tendering, smaller hospitals organize tenders at a regional level. Therefore, these factors are anticipated to augment the companion diagnostics market growth in Europe over the estimated period.
COMPETITIVE INSIGHTS
Some of the leading firms operating in the market include Almac Group, Biocartis, Biomerieux, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
137 Pages
- 1. Research Scope & Methodology
- 1.1. Study Objectives
- 1.2. Scope Of Study
- 1.3. Methodology
- 1.4. Assumptions & Limitations
- 2. Executive Summary
- 2.1. Market Size & Estimates
- 2.2. Market Overview
- 3. Market Dynamics
- 3.1. Key Drivers
- 3.1.1. Growing Number Of Cancer Cases And Mortalities
- 3.1.2. Increasing Popularity Of Precision Medicines
- 3.1.3. Rising Number Of Adverse Drug Reaction Cases
- 3.2. Key Restraints
- 3.2.1. Country-specific Reimbursement Issues
- 3.2.2. Frequent Cases Of Leakage In Companion Diagnostics For Oncology
- 4. Key Analytics
- 4.1. Impact Of Covid-19 On Companion Diagnostics Market
- 4.2. Key Market Trends
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Buyers Power
- 4.3.2. Suppliers Power
- 4.3.3. Substitution
- 4.3.4. New Entrants
- 4.3.5. Industry Rivalry
- 4.4. Opportunity Matrix
- 4.5. Vendor Landscape
- 4.6. Value Chain Analysis
- 4.7. Key Buying Criteria
- 4.8. Regulatory Framework
- 5. Market By Technology
- 5.1. In Situ Hybridization
- 5.2. Polymerase Chain Reaction
- 5.3. Immunohistochemistry
- 5.4. Next Generation Sequencing
- 5.5. Other Technologies
- 6. Market By Indication
- 6.1. Oncology
- 6.2. Neurology
- 6.3. Infectious Diseases
- 6.4. Other Indications
- 7. Market By End-user
- 7.1. Pharmaceutical And Biopharmaceutical Companies
- 7.2. Reference Laboratories
- 7.3. Other End-users
- 8. Market By Products & Services
- 8.1. Assay Kits And Reagents
- 8.2. Software & Services
- 9. Geographical Analysis
- 9.1. Europe
- 9.1.1. Market Size & Estimates
- 9.1.2. Key Growth Enablers
- 9.1.3. Key Challenges
- 9.1.4. Key Players
- 9.1.5. Country Analysis
- 9.1.5.1. United Kingdom
- 9.1.5.2. Germany
- 9.1.5.3. France
- 9.1.5.4. Spain
- 9.1.5.5. Italy
- 9.1.5.6. Poland
- 9.1.5.7. Netherlands
- 9.1.5.8. Rest Of Europe
- 10. Competitive Landscape
- 10.1. Key Strategic Developments
- 10.1.1. Mergers & Acquisitions
- 10.1.2. Product Launches & Developments
- 10.1.3. Partnerships & Agreements
- 10.2. Company Profiles
- 10.2.1. Abbott Laboratories
- 10.2.2. Agilent
- 10.2.3. Alamc Group
- 10.2.4. Arup Laboratories
- 10.2.5. Biocartis
- 10.2.6. Biomerieux Sa
- 10.2.7. Danaher Corporation
- 10.2.8. Ge Healthcare
- 10.2.9. Genomic Health
- 10.2.10. Illumina Inc
- 10.2.11. Myriad Genetics Inc
- 10.2.12. Qiagen Nv
- 10.2.13. Roche Diagnostics
- 10.2.14. Sysmex Corporation
- 10.2.15. Thermo Fisher Scientific Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
